High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Key Points: Patient-specific pathways of resistance to venetoclax can be identified by high-content screening of clinical samples with a KI library. Sunitinib may overcome resistance to venetoclax for many patients by downregulating the expression of Bcl-xl, Mcl-1, and A1 in CLL cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
The IL-4 receptor: signaling mechanisms and biologic functions
Nelms, K., Keegan, A. D., Zamorano, J., Ryan, J. J., & Paul, W. E. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.701 · Cited by 1,545 · cited 1×
“To confirm these results, IL4 was used as an alternative method to mimic the leukemic microenvironment.(24-27) The venetoclax dose response in 2S-stimulated cells was plotted against the dose response in IL4-stimulated cells and positive correlations were obtained for each of the single assays (Annexin V, R(2) 5 0.”
MethodEssential versus accessory aspects of cell death: recommendations of the NCCD 2015
Galluzzi, L., Bravo-San Pedro, J. M., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Alnemri, E. S., Altucci, L., Andrews, D., Annicchiarico-Petruzzelli, M., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.137 · Cited by 1,002
Self-citationPatient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708 · cited 2×
“Genetic heterogeneity and activation of patient-specific bypass pathways likely contribute to therapy resistance.(11) Overcoming these barriers and being able to rapidly identify drugs or drug combinations that would be effective in individual patients would be an important advance.”
BackgroundPonader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4642 · Cited by 541 · cited 1×
“As an indirect inhibitor of Bcl-xl, sunitinib may be a better alternative for clinical use without the on-target side effect of thrombocytopenia caused by navitoclax.(61-64) Sunitinib targets multiple tyrosine kinases, such as PDFRs, KIT, FLT3, and VEGF, suggesting a role for these pathways in CLL biology that is rela…”
BackgroundRhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
Kwiatkowski, D. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.446 · Cited by 387
BCL-2 is dispensable for thrombopoiesis and platelet survival
Debrincat, M. A., Pleines, I., Lebois, M., Lane, R. M., Holmes, M. L., Corbin, J., Vandenberg, C. J., Alexander, W. S., Ng, A. P., Strasser, A., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.97 · Cited by 92
Research works printed but not linked: 71
- Meads, 2008, The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance., Clin Cancer Res, 14, 2519, 10.1158/1078-0432.CCR-07-2223 · DOI · Paper page
- Burger, 2000, Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1., Blood, 96, 2655, 10.1182/blood.V96.8.2655 · DOI · Paper page
- Kurtova, 2009, Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance., Blood, 114, 4441, 10.1182/blood-2009-07-233718 · DOI · Paper page
- Vogler, 2009, Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia., Blood, 113, 4403, 10.1182/blood-2008-08-173310 · DOI · Paper page
- Brahmbhatt, 2015, Molecular pathways: leveraging the BCL-2 interactome to kill cancer cells--mitochondrial outer membrane permeabilization and beyond., Clin Cancer Res, 21, 2671, 10.1158/1078-0432.CCR-14-0959 · DOI
- Cimmino, 2005, miR-15 and miR-16 induce apoptosis by targeting BCL2 [published correction appears in Proc Natl Acad Sci USA. 2006;103(7):2464]., Proc Natl Acad Sci USA, 102, 13944, 10.1073/pnas.0506654102 · DOI · Paper page
- Smit, 2007, Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity., Blood, 109, 1660, 10.1182/blood-2006-05-021683 · DOI · Paper page
- Anderson, 2016, The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53 independent mechanism., Blood, 127, 3215, 10.1182/blood-2016-01-688796 · DOI · Paper page
- Roberts, 2016, Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia., N Engl J Med, 374, 311, 10.1056/NEJMoa1513257 · DOI · Paper page
- Souers, 2013, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets., Nat Med, 19, 202, 10.1038/nm.3048 · DOI · Paper page
- Spaner, 2013, PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia., Leukemia, 27, 1090, 10.1038/leu.2012.329 · DOI
- Tomic, 2006, Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity., J Immunol, 176, 3830, 10.4049/jimmunol.176.6.3830 · DOI
- Spaner, 2006, Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells., Leukemia, 20, 286, 10.1038/sj.leu.2404061 · DOI
- Shen, 2013, Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs [published correction appears at http://dx.doi.org/10.1371/annotation/e2536fcb-3ab3-44a0-8eab-91aaeb8e49b6]., PLoS One, 8, e75252, 10.1371/journal.pone.0075252 · DOI
- Thijssen, 2015, Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors., Haematologica, 100, e302
- Crassini, 2015, The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine., Leuk Lymphoma, 56, 3407, 10.3109/10428194.2015.1032963 · doi:10.3109/10428194.2015.1032963
- Crassini, 2015, Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: a review of the in vitro and clinical trials to date., World J Clin Cases, 3, 694, 10.12998/wjcc.v3.i8.694 · DOI
- Li, 2015, Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A., Blood, 126, 766, 10.1182/blood-2014-12-618678 · DOI
- Lessene, 2008, BCL-2 family antagonists for cancer therapy., Nat Rev Drug Discov, 7, 989, 10.1038/nrd2658 · DOI · Paper page
- Kepp, 2011, Cell death assays for drug discovery., Nat Rev Drug Discov, 10, 221, 10.1038/nrd3373 · DOI · Paper page
- Collins, 2015, A versatile cell death screening assay using dye-stained cells and multivariate image analysis., Assay Drug Dev Technol, 13, 547, 10.1089/adt.2015.661 · DOI
- Douglas, 1997, Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta., Blood, 89, 941, 10.1182/blood.V89.3.941 · DOI
- Panayiotidis, 1993, Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro., Br J Haematol, 85, 439, 10.1111/j.1365-2141.1993.tb03330.x · DOI · Paper page
- Steele, 2010, The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment., Blood, 116, 4569, 10.1182/blood-2009-09-245811 · DOI
- de Totero, 1999, IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia., Br J Haematol, 104, 589, 10.1046/j.1365-2141.1999.01219.x · DOI
- Kay, 2001, Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis., Br J Haematol, 112, 760, 10.1046/j.1365-2141.2001.02605.x · doi:10.1046/j.1365-2141.2001.02605.x
- Rossmann, 2002, Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL)., Eur J Haematol, 68, 299, 10.1034/j.1600-0609.2002.01612.x · doi:10.1034/j.1600-0609.2002.01612.x
- Chow, 2007, Sunitinib: from rational design to clinical efficacy., J Clin Oncol, 25, 884, 10.1200/JCO.2006.06.3602 · DOI · Paper page
- Christensen, 2007, A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities., Ann Oncol, 18, x3, 10.1093/annonc/mdm408 · DOI
- Ebos, 2007, Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy., Proc Natl Acad Sci USA, 104, 17069, 10.1073/pnas.0708148104 · DOI · Paper page
- Henderson, 2015, A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib., eLife, 4, e08351, 10.7554/eLife.08351 · DOI · Paper page
- Shanafelt, 2010, Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia., Leuk Lymphoma, 51, 2222, 10.3109/10428194.2010.524327 · doi:10.3109/10428194.2010.524327
- Claus, 2012, A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR., Epigenetics, 7, 772, 10.4161/epi.20299 · DOI · Paper page
- Kröber, 2002, V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia., Blood, 100, 1410, 10.1182/blood.V100.4.1410.h81602001410_1410_1416 · DOI · Paper page
- Mertens, 2014, Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?, J Clin Oncol, 32, 869, 10.1200/JCO.2013.53.8421 · DOI
- Oakes, 2016, DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia., Nat Genet, 48, 253, 10.1038/ng.3488 · DOI · Paper page
- Queirós, 2015, A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact., Leukemia, 29, 598, 10.1038/leu.2014.252 · DOI · Paper page
- Longo, 2008, The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells., Blood, 111, 846, 10.1182/blood-2007-05-089037 · DOI · Paper page
- Purroy, 2014, Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein., Leukemia, 28, 1993, 10.1038/leu.2014.96 · DOI
- Néron, 1996, Induction of LFA-1 independent human B cell proliferation and differentiation by binding of CD40 with its ligand., Immunol Invest, 25, 79, 10.3109/08820139609059292 · doi:10.3109/08820139609059292
- Soderquist, 2013, Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo., Leukemia, 27, 2262, 10.1038/leu.2013.138 · doi:10.1038/leu.2013.138
- Willimott, 2007, CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia., Br J Haematol, 138, 721, 10.1111/j.1365-2141.2007.06717.x · DOI
- Willimott, 2007, Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4., Haematologica, 92, 1359, 10.3324/haematol.11340 · doi:10.3324/haematol.11340
- Brown, 2014, Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia., Blood, 123, 3390, 10.1182/blood-2013-11-535047 · DOI · Paper page
- Woyach, 2015, Targeted therapies in CLL: mechanisms of resistance and strategies for management., Blood, 126, 471, 10.1182/blood-2015-03-585075 · DOI
- Del Gaizo Moore, 2007, Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737., J Clin Invest, 117, 112, 10.1172/JCI28281 · DOI · Paper page
- Tromp, 2010, Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering., Oncogene, 29, 5071, 10.1038/onc.2010.248 · DOI
- Davids, 2012, Targeting the B cell receptor pathway in chronic lymphocytic leukemia., Leuk Lymphoma, 53, 2362, 10.3109/10428194.2012.695781 · DOI
- Herishanu, 2011, The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia., Blood, 117, 563, 10.1182/blood-2010-05-284984 · DOI · Paper page
- Rahmani, 2012, Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process., Blood, 119, 6089, 10.1182/blood-2011-09-378141 · DOI
- Abrams, 2003, Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer., Mol Cancer Ther, 2, 1011
- Abrams, 2003, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer., Mol Cancer Ther, 2, 471
- Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship., Clin Cancer Res, 9, 327
- Murray, 2003, SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model., Clin Exp Metastasis, 20, 757, 10.1023/B:CLIN.0000006873.65590.68 · DOI · Paper page
- O’Farrell, 2003, SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo., Blood, 101, 3597, 10.1182/blood-2002-07-2307 · DOI · Paper page
- Kaefer, 2014, Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia., Cancer Chemother Pharmacol, 74, 593, 10.1007/s00280-014-2530-9 · DOI · Paper page
- Roberts, 2012, Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease., J Clin Oncol, 30, 488, 10.1200/JCO.2011.34.7898 · DOI · Paper page
- Cervantes-Gomez, 2015, Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia., Clin Cancer Res, 21, 3705, 10.1158/1078-0432.CCR-14-2809 · DOI · Paper page
- O’Brien, 2014, Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial., Lancet Oncol, 15, 48, 10.1016/S1470-2045(13)70513-8 · DOI · Paper page
- Martinez Marignac, 2013, Resistance to dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming., Oncotarget, 4, 2550, 10.18632/oncotarget.1508 · DOI
- Pitini, 2011, The role of p53 and autophagy in dasatinib resistance of CLL lymphocytes., Leuk Res, 35, 32, 10.1016/j.leukres.2010.07.007 · doi:10.1016/j.leukres.2010.07.007
- Amrein, 2011, The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms., Leuk Lymphoma, 52, 754, 10.3109/10428194.2011.555890 · DOI
- Amrein, 2011, Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia., Clin Cancer Res, 17, 2977, 10.1158/1078-0432.CCR-10-2879 · DOI · Paper page
- Eley, 2009, Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects., J Clin Pharmacol, 49, 700, 10.1177/0091270009333854 · DOI
- Hussain, 2008, Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium., Blood, 111, 3190, 10.1182/blood-2007-10-115733 · DOI
- Lin, 2008, Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies., Clin Lymphoma Myeloma, 8, S137, 10.3816/CLM.2008.s.009 · DOI
- Lanasa, 2015, Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia., Leuk Res, 39, 495, 10.1016/j.leukres.2015.02.001 · DOI
- Goodman, 2007, Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma., Clin Cancer Res, 13, 1367, 10.1158/1078-0432.CCR-06-2328 · DOI · Paper page
- Kronabel, 2015, Possible influence of some foods on the metabolism of ibrutinib., Clin Lab, 61, 443
- Rais, 2012, Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study., Biomed Chromatogr, 26, 1315, 10.1002/bmc.2697 · DOI
- Weiss, 2016, Venetoclax (ABT-199) might act as a perpetrator in pharmacokinetic drug-drug interactions., Pharmaceutics, 8, 10.3390/pharmaceutics8010005 · DOI
Cited by
Alshetaiwi, H., Pervolarakis, N., McIntyre, L. L., Ma, D., Nguyen, Q., Rath, J. A., Nee, K., Hernandez, G., Evans, K., Torosian, L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aay6017 · Cited by 537
Tron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L. H., Chiarparin, E., Cidado, J., Embrey, K. J., Gangl, E., Gibbons, F. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07551-w · Cited by 490
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.005 · Cited by 361
Pathways and mechanisms of venetoclax resistance
Bose, P., Gandhi, V., & Konopleva, M. (2017) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1283032 · Cited by 302
Metadata
- Authors
- Oppermann, S., Ylanko, J., Shi, Y., Hariharan, S., Oakes, C. C., Brauer, P. M., Zúñiga-Pflücker, J. C., Leber, B., Spaner, D. E., & Andrews, D. W.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-08-18
- Volume
- 128
- Issue
- 7
- Pages
- 934-947
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2510710599
- Cited by
- 122
- References
- 8
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. https://app.cochat.ai/papers/10.1182/blood-2015-12-687814
- The paper
- Oppermann, S., Ylanko, J., Shi, Y., Hariharan, S., Oakes, C. C., Brauer, P. M., Zúñiga-Pflücker, J. C., Leber, B., Spaner, D. E., & Andrews, D. W. (2016). High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood. https://doi.org/10.1182/blood-2015-12-687814
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.